trending Market Intelligence /marketintelligence/en/news-insights/trending/QV6jyYtEYa-pB6PfrTSpvA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

NeoGenomics acquires cancer treatment unit from Human Longevity

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

NeoGenomics acquires cancer treatment unit from Human Longevity

NeoGenomics Inc. has completed its acquisition of private company Human Longevity Inc.'s cancer treatment unit for $37 million in cash.

NeoGenomics expects the acquisition to be slightly dilutive to the company's adjusted EBITDA this year before turning accretive in 2021.

"This acquisition will expand our Pharma Services menu to include germline, whole exome and whole genome sequencing," NeoGenomics CEO and Chairman Douglas VanOort said in a statement.

Human Longevity's cancer unit performs modern techniques for DNA sequencing dubbed next-generation sequencing.

In May 2019, NeoGenomics priced a common stock offering to raise $148.8 million for potential acquisitions or investments and general corporate purposes.

Fort Myers, Fla.-based NeoGenomics operates cancer genetics testing laboratories.